Ftse Mib
34.780,81
1,91%
DAX
20.216,19
1,54%
S&P 500
5.975,38
0,55%
NASDAQ
19.864,98
1,24%
Bitcoin
101.938,87
-0,34%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Silo Pharma Inc (SILO) Silo Pharma Inc (SILO) Notizie

SILO

Silo Pharma (SILO)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:SILO
DataOraFonteTitoloSimboloCompagnia
02/01/202517:11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SILOSilo Pharma Inc
02/01/202514:45GlobeNewswire Inc.Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic PainNASDAQ:SILOSilo Pharma Inc
18/12/202413:35GlobeNewswire Inc.Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and FibromyalgiaNASDAQ:SILOSilo Pharma Inc
16/12/202423:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SILOSilo Pharma Inc
29/11/202414:05GlobeNewswire Inc.Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain ManagementNASDAQ:SILOSilo Pharma Inc
18/11/202414:40GlobeNewswire Inc.Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related DisordersNASDAQ:SILOSilo Pharma Inc
15/11/202423:21Edgar (US Regulatory)Form DEFR14A - Revised definitive proxy soliciting materialsNASDAQ:SILOSilo Pharma Inc
12/11/202422:42Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SILOSilo Pharma Inc
08/11/202422:04Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:SILOSilo Pharma Inc
31/10/202413:35GlobeNewswire Inc.Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine ImplantNASDAQ:SILOSilo Pharma Inc
18/09/202422:19Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:SILOSilo Pharma Inc
18/09/202422:15Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:SILOSilo Pharma Inc
10/09/202412:35GlobeNewswire Inc.Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSDNASDAQ:SILOSilo Pharma Inc
04/09/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SILOSilo Pharma Inc
21/08/202423:20Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:SILOSilo Pharma Inc
14/08/202420:30GlobeNewswire Inc.Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant TherapeuticNASDAQ:SILOSilo Pharma Inc
07/08/202414:13GlobeNewswire Inc.Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing PeptideNASDAQ:SILOSilo Pharma Inc
02/08/202419:16Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:SILOSilo Pharma Inc
26/07/202422:17Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:SILOSilo Pharma Inc
26/07/202414:20GlobeNewswire Inc.Silo Pharma to Present at H.C. Wainwright Annual Global Investment ConferenceNASDAQ:SILOSilo Pharma Inc
25/07/202422:30Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:SILOSilo Pharma Inc
22/07/202422:45GlobeNewswire Inc.Silo Pharma Announces Closing of $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesNASDAQ:SILOSilo Pharma Inc
22/07/202412:06Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SILOSilo Pharma Inc
19/07/202414:01GlobeNewswire Inc.Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesNASDAQ:SILOSilo Pharma Inc
18/07/202414:25GlobeNewswire Inc.Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15NASDAQ:SILOSilo Pharma Inc
16/07/202412:30GlobeNewswire Inc.Silo Pharma Secures Exclusive Global License for Alzheimer's TherapeuticNASDAQ:SILOSilo Pharma Inc
08/07/202414:45GlobeNewswire Inc.Silo Pharma Announces Exclusive, Global License for Lead Candidate SPC-15 Targeting PTSD and Stress-Induced Anxiety DisordersNASDAQ:SILOSilo Pharma Inc
26/06/202414:50GlobeNewswire Inc.Silo Pharma Partners with AmplifyBio to Advance SPC-15 for PTSD and AnxietyNASDAQ:SILOSilo Pharma Inc
13/06/202423:08Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:SILOSilo Pharma Inc
07/06/202414:18GlobeNewswire Inc.Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for FibromyalgiaNASDAQ:SILOSilo Pharma Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:SILO

La tua Cronologia

LSE
HAT
H&t
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network